Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.
Novartis to buy siRNA developer DTx Pharma for up to $1B
Novartis will continue to add siRNA capabilities to its tool belt in a deal worth up to $1 billion. The Swiss pharma acquired DTx Pharma,